Literature DB >> 21435462

Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.

Cheryl M Koh1, Bora Gurel, Siobhan Sutcliffe, Martin J Aryee, Denise Schultz, Tsuyoshi Iwata, Motohide Uemura, Karen I Zeller, Uzoma Anele, Qizhi Zheng, Jessica L Hicks, William G Nelson, Chi V Dang, Srinivasan Yegnasubramanian, Angelo M De Marzo.   

Abstract

Increased nucleolar size and number are hallmark features of many cancers. In prostate cancer, nucleolar enlargement and increased numbers are some of the earliest morphological changes associated with development of premalignant prostate intraepithelial neoplasia (PIN) lesions and invasive adenocarcinomas. However, the molecular mechanisms that induce nucleolar alterations in PIN and prostate cancer remain largely unknown. We verify that activation of the MYC oncogene, which is overexpressed in most human PIN and prostatic adenocarcinomas, leads to formation of enlarged nucleoli and increased nucleolar number in prostate luminal epithelial cells in vivo. In prostate cancer cells in vitro, MYC expression is needed for maintenance of nucleolar number, and a nucleolar program of gene expression. To begin to decipher the functional relevance of this transcriptional program in prostate cancer, we examined FBL (encoding fibrillarin), a MYC target gene, and report that fibrillarin is required for proliferation, clonogenic survival, and proper ribosomal RNA accumulation/processing in human prostate cancer cells. Further, fibrillarin is overexpressed in PIN lesions induced by MYC overexpression in the mouse prostate, and in human clinical prostate adenocarcinoma and PIN lesions, where its expression correlates with MYC levels. These studies demonstrate that overexpression of the MYC oncogene increases nucleolar number and size and a nucleolar program of gene expression in prostate epithelial cells, thus providing a molecular mechanism responsible for hallmark nucleolar alterations in prostatic neoplasia.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435462      PMCID: PMC3078425          DOI: 10.1016/j.ajpath.2010.12.040

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

Review 1.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

2.  Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.

Authors:  R Buttyan; I S Sawczuk; M C Benson; J D Siegal; C A Olsson
Journal:  Prostate       Date:  1987       Impact factor: 4.104

3.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

Review 4.  Does the ribosome translate cancer?

Authors:  Davide Ruggero; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

5.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

6.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 7.  Nucleolus, ribosomes, and cancer.

Authors:  Lorenzo Montanaro; Davide Treré; Massimo Derenzini
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

8.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

9.  Immortalization of primary human prostate epithelial cells by c-Myc.

Authors:  Jesús Gil; Preeti Kerai; Matilde Lleonart; David Bernard; Juan Cruz Cigudosa; Gordon Peters; Amancio Carnero; David Beach
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 13.312

10.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.

Authors:  Karen I Zeller; Anil G Jegga; Bruce J Aronow; Kathryn A O'Donnell; Chi V Dang
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

View more
  57 in total

1.  Heterozygous De Novo UBTF Gain-of-Function Variant Is Associated with Neurodegeneration in Childhood.

Authors:  Simon Edvardson; Claudia M Nicolae; Pankaj B Agrawal; Cyril Mignot; Katelyn Payne; Asuri Narayan Prasad; Chitra Prasad; Laurie Sadler; Caroline Nava; Thomas E Mullen; Amber Begtrup; Berivan Baskin; Zöe Powis; Avraham Shaag; Boris Keren; George-Lucian Moldovan; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2017-08-03       Impact factor: 11.025

Review 2.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 3.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 4.  The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenes.

Authors:  J G Sinkovics
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

5.  Loss of the integral nuclear envelope protein SUN1 induces alteration of nucleoli.

Authors:  Ayaka Matsumoto; Chiyomi Sakamoto; Haruka Matsumori; Jun Katahira; Yoko Yasuda; Katsuhide Yoshidome; Masahiko Tsujimoto; Ilya G Goldberg; Nariaki Matsuura; Mitsuyoshi Nakao; Noriko Saitoh; Miki Hieda
Journal:  Nucleus       Date:  2016-03-10       Impact factor: 4.197

6.  RNA modifications and cancer.

Authors:  Phensinee Haruehanroengra; Ya Ying Zheng; Yubin Zhou; Yun Huang; Jia Sheng
Journal:  RNA Biol       Date:  2020-02-07       Impact factor: 4.652

7.  Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.

Authors:  Laxmi G Pellakuru; Tsuyoshi Iwata; Bora Gurel; Denise Schultz; Jessica Hicks; Carlise Bethel; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2012-06-17       Impact factor: 4.307

Review 8.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

Review 9.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

10.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.